DNA technology as a novel strategy for delivery of anti-HIV antibodies
Synthetic DMAbs allow for in vivo production of broadly neutralizing antibodies in preclinical studiesCredit: The Wistar Institute PHILADELPHIA -- (Nov. 8, 2019) -- Scientists at...
















